{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:33:15Z","timestamp":1740123195066,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/3-015-02\/503-31-001"],"award-info":[{"award-number":["503\/3-015-02\/503-31-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple myeloma is one of the most common hematological malignancies worldwide. Genetic alterations may lead to the progression from monoclonal gammopathy to multiple myeloma. Additionally, the genetic background of the disease might influence therapy outcomes, including survival time. SLCO1B1, belonging to the OATPs family, is a membrane protein that mediates the uptake of a wide range of endogenous and exogenous (including drugs) compounds.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>In this study, the A388G single nucleotide polymorphism in the <jats:italic>SLCO1B1<\/jats:italic> gene in Polish multiple myeloma patients was determined. This polymorphism affects the amino acid change of the protein, so it may be responsible for treatment effectiveness or risk of disease development. A388G was evaluated by the PCR\u2013RFLP method. The presented study showed a statistically significant association between the GG genotype with longer survival of patients with multiple myeloma with Melphalan-Prednisone therapy compared to other treatment regimens (<jats:italic>p<\/jats:italic>\u2009=\u20090.0271). There was no statistically significant association in the frequency of genotypes (<jats:italic>p<\/jats:italic>\u2009=\u20090.8211) and alleles: allele A (<jats:italic>p<\/jats:italic>\u2009=\u20090.5442); allele G (<jats:italic>p<\/jats:italic>\u2009=\u20090.8020) between multiple myeloma patients and a control group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The A388G polymorphism does not seem to affect the increased risk of the development of multiple myeloma. However, the occurrence of the GG genotype may prolong of patients overall survival in the case of Melphalan-Prednisone therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11033-022-08162-x","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T07:03:22Z","timestamp":1670396602000},"page":"1447-1458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters, treatment, and survival of multiple myeloma cases in a Polish population"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2964-4793","authenticated-orcid":false,"given":"Katarzyna","family":"Michalska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-2914","authenticated-orcid":false,"given":"Ewa","family":"Balcerczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3565-7075","authenticated-orcid":false,"given":"Agnieszka","family":"Jele\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0793-3546","authenticated-orcid":false,"given":"Lias","family":"Saed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9187-1199","authenticated-orcid":false,"given":"Jacek","family":"Pietrzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7478-7860","authenticated-orcid":false,"given":"Marta","family":"\u017bebrowska-Nawrocka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"8162_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5644\/ama2006-124.242","volume":"48","author":"O Castaneda","year":"2019","unstructured":"Castaneda O, Baz R (2019) Multiple myeloma genomics - a concise review. Acta Med Acad 48:57\u201367. https:\/\/doi.org\/10.5644\/ama2006-124.242","journal-title":"Acta Med Acad"},{"key":"8162_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123576","author":"MA Legarda","year":"2020","unstructured":"Legarda MA, Cejalvo MJ, de la Rubia J (2020) Recent advances in the treatment of patients with multiple myeloma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12123576","journal-title":"Cancers (Basel)"},{"key":"8162_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-00291-4","author":"D Chen","year":"2021","unstructured":"Chen D, Yang X, Liu M, Zhang Z, Xing E (2021) Roles of miRNA dysregulation in the pathogenesis of multiple myeloma. Cancer Gene Ther. https:\/\/doi.org\/10.1038\/s41417-020-00291-4","journal-title":"Cancer Gene Ther"},{"key":"8162_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.tranon.2019.04.023","volume":"12","author":"S Wang","year":"2019","unstructured":"Wang S, Ma Y, Wang X, Jiang J, Zhang C, Jiang Y, Huang H, Hong L (2019) IL-17A increases multiple myeloma cell viability by positively regulating syk expression. Transl Oncol 12:1086\u20131091. https:\/\/doi.org\/10.1016\/j.tranon.2019.04.023","journal-title":"Transl Oncol"},{"key":"8162_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356\u2013387. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.005","journal-title":"Eur J Cancer"},{"key":"8162_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"8162_CR7","first-page":"373","volume":"95","author":"TC Michels","year":"2017","unstructured":"Michels TC, Petersen KE (2017) Multiple myeloma: diagnosis and treatment. Am Fam Physician 95:373\u2013383","journal-title":"Am Fam Physician"},{"key":"8162_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/hon.2469","volume":"36","author":"T Kasamatsu","year":"2018","unstructured":"Kasamatsu T, Kimoto M, Takahashi N, Minato Y, Gotoh N, Takizawa M, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Saitoh T, Murakami H (2018) IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma. Hematol Oncol 36:196\u2013201. https:\/\/doi.org\/10.1002\/hon.2469","journal-title":"Hematol Oncol"},{"key":"8162_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","volume":"165","author":"M Roth","year":"2012","unstructured":"Roth M, Obaidat A, Hagenbuch B (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165:1260\u20131287. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01724.x","journal-title":"Br J Pharmacol"},{"key":"8162_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1208\/s12248-015-9740-x","volume":"17","author":"N Thakkar","year":"2015","unstructured":"Thakkar N, Lockhart AC, Lee W (2015) Role of organic anion-transporting polypeptides (OATPs) in cancer therapy. Aaps J 17:535\u2013545. https:\/\/doi.org\/10.1208\/s12248-015-9740-x","journal-title":"Aaps J"},{"key":"8162_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/bcp.13207","volume":"83","author":"HH Lee","year":"2017","unstructured":"Lee HH, Ho RH (2017) Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol 83:1176\u20131184. https:\/\/doi.org\/10.1111\/bcp.13207","journal-title":"Br J Clin Pharmacol"},{"key":"8162_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-pharmtox-010510-100556","volume":"52","author":"A Obaidat","year":"2012","unstructured":"Obaidat A, Roth M, Hagenbuch B (2012) The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 52:135\u2013151. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010510-100556","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"8162_CR13","doi-asserted-by":"publisher","first-page":"863539","DOI":"10.1155\/2013\/863539","volume":"2013","author":"V Buxhofer-Ausch","year":"2013","unstructured":"Buxhofer-Ausch V, Secky L, Wlcek K, Svoboda M, Kounnis V, Briasoulis E, Tzakos AG, Jaeger W, Thalhammer T (2013) Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv 2013:863539. https:\/\/doi.org\/10.1155\/2013\/863539","journal-title":"J Drug Deliv"},{"key":"8162_CR14","doi-asserted-by":"publisher","first-page":"114649","DOI":"10.1016\/j.taap.2019.114649","volume":"379","author":"X Lin","year":"2019","unstructured":"Lin X, Xiang Z, Wang B, Chen H, Zhou T, Hong M (2019) Interaction of swine organic anion transporting polypeptide 1a2 with tetracycline, macrolide and \u03b2-lactam antibiotics. Toxicol Appl Pharmacol 379:114649. https:\/\/doi.org\/10.1016\/j.taap.2019.114649","journal-title":"Toxicol Appl Pharmacol"},{"key":"8162_CR15","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3892\/or.2017.5727","volume":"38","author":"CM Gao","year":"2017","unstructured":"Gao CM, Pu Z, He C, Liang D, Jia Y, Yuan X, Wang G, Xie H (2017) Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen. Oncol Rep 38:1124\u20131132. https:\/\/doi.org\/10.3892\/or.2017.5727","journal-title":"Oncol Rep"},{"key":"8162_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/jcpt.12569","volume":"42","author":"BJ Gregory","year":"2017","unstructured":"Gregory BJ, Chen SM, Murphy MA, Atchley DH, Kamdem LK (2017) Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers. J Clin Pharm Ther 42:547\u2013553. https:\/\/doi.org\/10.1111\/jcpt.12569","journal-title":"J Clin Pharm Ther"},{"key":"8162_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.addr.2016.06.004","volume":"116","author":"F Zhou","year":"2017","unstructured":"Zhou F, Zhu L, Wang K, Murray M (2017) Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition. Adv Drug Deliv Rev 116:21\u201336. https:\/\/doi.org\/10.1016\/j.addr.2016.06.004","journal-title":"Adv Drug Deliv Rev"},{"key":"8162_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030855","author":"K Alam","year":"2018","unstructured":"Alam K, Crowe A, Wang X, Zhang P, Ding K, Li L, Yue W (2018) Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19030855","journal-title":"Int J Mol Sci"},{"key":"8162_CR19","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1124\/dmd.105.005926","volume":"33","author":"X Wang","year":"2005","unstructured":"Wang X, Wolkoff AW, Morris ME (2005) Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33:1666\u20131672. https:\/\/doi.org\/10.1124\/dmd.105.005926","journal-title":"Drug Metab Dispos"},{"key":"8162_CR20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1124\/mol.118.114314","volume":"95","author":"RR Schulte","year":"2019","unstructured":"Schulte RR, Ho RH (2019) Organic anion transporting polypeptides: emerging roles in cancer pharmacology. Mol Pharmacol 95:490\u2013506. https:\/\/doi.org\/10.1124\/mol.118.114314","journal-title":"Mol Pharmacol"},{"key":"8162_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12885-017-3728-0","volume":"17","author":"S Falkowski","year":"2017","unstructured":"Falkowski S, Woillard JB, Postil D, Tubiana-Mathieu N, Terrebonne E, Pariente A, Smith D, Guimbaud R, Thalamas C, Rouguieg-Malki K, Marquet P, Picard N (2017) Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study. BMC Cancer 17:901. https:\/\/doi.org\/10.1186\/s12885-017-3728-0","journal-title":"BMC Cancer"},{"key":"8162_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/cpt.315","volume":"99","author":"CD Drenberg","year":"2016","unstructured":"Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD (2016) Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther 99:651\u2013660. https:\/\/doi.org\/10.1002\/cpt.315","journal-title":"Clin Pharmacol Ther"},{"key":"8162_CR23","first-page":"770","volume":"52","author":"H Zhang","year":"2014","unstructured":"Zhang H, He X, Li J, Wang Y, Wang C, Chen Y, Niu C, Gao P (2014) SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia. Zhonghua Er Ke Za Zhi 52:770\u2013776","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"8162_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/cts.12879","volume":"14","author":"RR Schulte","year":"2021","unstructured":"Schulte RR, Choi L, Utreja N, Van Driest SL, Stein CM, Ho RH (2021) Effect of SLCO1B1 polymorphisms on high-dose methotrexate clearance in children and young adults with leukemia and lymphoblastic lymphoma. Clin Transl Sci 14:343\u2013353. https:\/\/doi.org\/10.1111\/cts.12879","journal-title":"Clin Transl Sci"},{"key":"8162_CR25","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3892\/or.2015.3864","volume":"33","author":"Z Pu","year":"2015","unstructured":"Pu Z, Zhang X, Chen Q, Yuan X, Xie H (2015) Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells. Oncol Rep 33:2420\u20132428. https:\/\/doi.org\/10.3892\/or.2015.3864","journal-title":"Oncol Rep"},{"key":"8162_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12863-015-0262-4","volume":"16","author":"A Nagy","year":"2015","unstructured":"Nagy A, Sipeky C, Szalai R, Melegh BI, Matyas P, Ganczer A, Toth K, Melegh B (2015) Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations. BMC Genet 16:108. https:\/\/doi.org\/10.1186\/s12863-015-0262-4","journal-title":"BMC Genet"},{"key":"8162_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2009.54","volume":"10","author":"SP Romaine","year":"2010","unstructured":"Romaine SP, Bailey KM, Hall AS, Balmforth AJ (2010) The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 10:1\u201311. https:\/\/doi.org\/10.1038\/tpj.2009.54","journal-title":"Pharmacogenomics J"},{"key":"8162_CR28","first-page":"19","volume":"13","author":"TM Sissung","year":"2012","unstructured":"Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD (2012) Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med 13:19\u201334","journal-title":"Discov Med"},{"key":"8162_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/tpj.2015.35","volume":"16","author":"S Noci","year":"2016","unstructured":"Noci S, Dugo M, Bertola F, Melotti F, Vannelli A, Dragani TA, Galvan A (2016) A subset of genetic susceptibility variants for colorectal cancer also has prognostic value. Pharmacogenomics J 16:173\u2013179. https:\/\/doi.org\/10.1038\/tpj.2015.35","journal-title":"Pharmacogenomics J"},{"key":"8162_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.gene.2018.07.031","volume":"676","author":"R Liutkeviciene","year":"2018","unstructured":"Liutkeviciene R, Vilkeviciute A, Slavinskaite A, Petrauskaite A, Tatarunas V, Kriauciuniene L (2018) Evaluation of serum SLCO1B1 levels and genetic variants of SLCO1B1 rs4149056 and rs2306283 in patients with early and exudative age-related macular degeneration. Gene 676:139\u2013145. https:\/\/doi.org\/10.1016\/j.gene.2018.07.031","journal-title":"Gene"},{"key":"8162_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11095-019-2634-3","volume":"36","author":"A Crowe","year":"2019","unstructured":"Crowe A, Zheng W, Miller J, Pahwa S, Alam K, Fung KM, Rubin E, Yin F, Ding K, Yue W (2019) Characterization of plasma membrane localization and phosphorylation status of organic anion transporting polypeptide (OATP) 1B1 c.521 T>C nonsynonymous single-nucleotide polymorphism. Pharm Res 36:101. https:\/\/doi.org\/10.1007\/s11095-019-2634-3","journal-title":"Pharm Res"},{"key":"8162_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/14622416.9.1.19","volume":"9","author":"MK Pasanen","year":"2008","unstructured":"Pasanen MK, Neuvonen PJ, Niemi M (2008) Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19\u201333. https:\/\/doi.org\/10.2217\/14622416.9.1.19","journal-title":"Pharmacogenomics"},{"key":"8162_CR33","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.7314\/apjcp.2016.17.3.1009","volume":"17","author":"C Basmaci","year":"2016","unstructured":"Basmaci C, Pehlivan M, Tomatir A, Sever T, Okan V, Yilmaz M, Oguzkan-Balci S, Pehlivan S (2016) Effects of TNFalpha, NOS3, MDR1 gene polymorphisms on clinical parameters, prognosis and survival of multiple myeloma cases. Asian Pac J Cancer Prev 17:1009\u20131014. https:\/\/doi.org\/10.7314\/apjcp.2016.17.3.1009","journal-title":"Asian Pac J Cancer Prev"},{"key":"8162_CR34","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","volume":"34","author":"B Hagenbuch","year":"2013","unstructured":"Hagenbuch B, Stieger B (2013) The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med 34:396\u2013412. https:\/\/doi.org\/10.1016\/j.mam.2012.10.009","journal-title":"Mol Aspects Med"},{"key":"8162_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/pcan.2016.42","volume":"20","author":"SM Green","year":"2017","unstructured":"Green SM, Kaipainen A, Bullock K, Zhang A, Lucas JM, Matson C, Banks WA, Mostaghel EA (2017) Role of OATP transporters in steroid uptake by prostate cancer cells in vivo. Prostate Cancer Prostatic Dis 20:20\u201327. https:\/\/doi.org\/10.1038\/pcan.2016.42","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"8162_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12957-020-01891-y","volume":"18","author":"S Chen","year":"2020","unstructured":"Chen S, Li K, Jiang J, Wang X, Chai Y, Zhang C, Deng Q, Shuai L, Feng K, Ma K, Zhang L (2020) Low expression of organic anion-transporting polypeptide 1B3 predicts a poor prognosis in hepatocellular carcinoma. World J Surg Oncol 18:127. https:\/\/doi.org\/10.1186\/s12957-020-01891-y","journal-title":"World J Surg Oncol"},{"key":"8162_CR37","doi-asserted-by":"publisher","first-page":"e0186924","DOI":"10.1371\/journal.pone.0186924","volume":"12","author":"K Alam","year":"2017","unstructured":"Alam K, Farasyn T, Crowe A, Ding K, Yue W (2017) Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner. PLoS ONE 12:e0186924. https:\/\/doi.org\/10.1371\/journal.pone.0186924","journal-title":"PLoS ONE"},{"key":"8162_CR38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3892\/ol.2020.12115","volume":"20","author":"V Buxhofer-Ausch","year":"2020","unstructured":"Buxhofer-Ausch V, N\u00e9met O, Sheikh M, Andrikovics H, Reiner A, Ausch C, Mechtcheriakova D, Tordai A, Gleiss A, \u00d6zvegy-Laczka C, J\u00e4ger W, Thalhammer T (2020) Two common polymorphic variants of OATP4A1 as potential risk factors for colorectal cancer. Oncol Lett 20:252. https:\/\/doi.org\/10.3892\/ol.2020.12115","journal-title":"Oncol Lett"},{"key":"8162_CR39","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00228-011-1065-9","volume":"67","author":"E Aklillu","year":"2011","unstructured":"Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, K\u00f6nig S, Ziesenitz V, Mikus G, Haefeli WE, Weiss J (2011) Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler\u00ae-based method. Eur J Clin Pharmacol 67:1139\u20131145. https:\/\/doi.org\/10.1007\/s00228-011-1065-9","journal-title":"Eur J Clin Pharmacol"},{"key":"8162_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/pr.110.002857","volume":"63","author":"M Niemi","year":"2011","unstructured":"Niemi M, Pasanen MK, Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157\u2013181. https:\/\/doi.org\/10.1124\/pr.110.002857","journal-title":"Pharmacol Rev"},{"key":"8162_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/bdd.1823","volume":"34","author":"Y Shitara","year":"2013","unstructured":"Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y (2013) Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos 34:45\u201378. https:\/\/doi.org\/10.1002\/bdd.1823","journal-title":"Biopharm Drug Dispos"},{"key":"8162_CR42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/gtmb.2012.0334","volume":"17","author":"G Ozhan","year":"2013","unstructured":"Ozhan G, Kara M, Sari FM, Yanar HT, Alpertunga B (2013) Influence of the functional polymorphisms in the organic anion transporting polypeptide 1B1 in the susceptibility to colorectal cancer. Genet Test Mol Biomarkers 17:214\u2013218. https:\/\/doi.org\/10.1089\/gtmb.2012.0334","journal-title":"Genet Test Mol Biomarkers"},{"key":"8162_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.12659\/msm.893473","volume":"21","author":"X Zhang","year":"2015","unstructured":"Zhang X, Pu Z, Ge J, Shen J, Yuan X, Xie H (2015) Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. Med Sci Monit 21:563\u2013569. https:\/\/doi.org\/10.12659\/msm.893473","journal-title":"Med Sci Monit"},{"key":"8162_CR44","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/bjc.2015.5","volume":"112","author":"WA Teft","year":"2015","unstructured":"Teft WA, Welch S, Lenehan J, Parfitt J, Choi YH, Winquist E, Kim RB (2015) OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer 112:857\u2013865. https:\/\/doi.org\/10.1038\/bjc.2015.5","journal-title":"Br J Cancer"},{"key":"8162_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00280-009-1138-y","volume":"66","author":"K Sai","year":"2010","unstructured":"Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H (2010) Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics\/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 66:95\u2013105. https:\/\/doi.org\/10.1007\/s00280-009-1138-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"8162_CR46","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/pbc.23074","volume":"57","author":"E Lopez-Lopez","year":"2011","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Pi\u00f1an MA, Garcia-Miguel P, Navajas A, Garcia-Orad A (2011) Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57:612\u2013619. https:\/\/doi.org\/10.1002\/pbc.23074","journal-title":"Pediatr Blood Cancer"},{"key":"8162_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.lungcan.2007.07.019","volume":"59","author":"JY Han","year":"2008","unstructured":"Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Kim HT, Lee JS (2008) Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59:69\u201375. https:\/\/doi.org\/10.1016\/j.lungcan.2007.07.019","journal-title":"Lung Cancer"},{"key":"8162_CR48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/cpt.1008","volume":"104","author":"D Martinez","year":"2018","unstructured":"Martinez D, Muhrez K, Woillard JB, Berthelot A, Gyan E, Choquet S, Andr\u00e8s CR, Marquet P, Barin-Le Guellec C (2018) Endogenous metabolites-mediated communication between OAT1\/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity. Clin Pharmacol Ther 104:687\u2013698. https:\/\/doi.org\/10.1002\/cpt.1008","journal-title":"Clin Pharmacol Ther"},{"key":"8162_CR49","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3389\/fphar.2020.00728","volume":"11","author":"C Na Nakorn","year":"2020","unstructured":"Na Nakorn C, Waisayarat J, Dejthevaporn C, Srisawasdi P, Wongwaisayawan S, Sukasem C (2020) Genetic variations and frequencies of the two functional single nucleotide polymorphisms of SLCO1B1 in the Thai population. Front Pharmacol 11:728. https:\/\/doi.org\/10.3389\/fphar.2020.00728","journal-title":"Front Pharmacol"},{"key":"8162_CR50","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1039\/c7sc05407f","volume":"9","author":"H Zhang","year":"2018","unstructured":"Zhang H, Liu J, Hu B, Wang L, Yang Z, Han X, Wang J, Bai W, Guo W (2018) Dual-channel fluorescence diagnosis of cancer cells\/tissues assisted by OATP transporters and cysteine\/glutathione. Chem Sci 9:3209\u20133214. https:\/\/doi.org\/10.1039\/c7sc05407f","journal-title":"Chem Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08162-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-08162-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08162-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T18:01:40Z","timestamp":1675188100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-08162-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["8162"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-08162-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"assertion":[{"value":"5 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The investigation was performed in accordance with the Declaration of Helsinki and the Good Laboratory Practice rules and was approved by the Ethical Committee of the Medical University of Lodz No: No: RNN\/93\/20\/KE, RNN\/88\/16\/KE; RNN\/285\/13\/KE.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}